Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Maximizing Impact and Utility of Prognostic Gene Testing in Melanoma and Squamous Cell Carcinoma : Episode 7

Opinion

Video

April 11, 2025

Determining Follow-Up Approach in Melanoma Based on GEP Risk Level

Author(s):

An expert discusses whether the 31-gene expression profile (GEP) risk classification would change treatment guidelines and how the patient’s GEP risk level would influence the approach to surveillance and follow-up.

EP: 1.Limitations and Challenges in Skin Cancer Staging Systems

EP: 2.Utility of Molecular Testing in Skin Cancer Risk Assessment

EP: 3.Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma

EP: 4.Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma

EP: 5.De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC

EP: 6.Key Takeaways on GEP Testing in Melanoma and SCC

Now Viewing

EP: 7.Determining Follow-Up Approach in Melanoma Based on GEP Risk Level

Video content above is prompted by the following:

Does the 31-GEP risk classification change your treatment guidelines?
How would you approach surveillance and follow-up with this patient after knowing their GEP risk level?

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!